Literature DB >> 2115543

IL-2. A cofactor for induction of activated macrophage resistance to infection.

M Belosevic1, D S Finbloom, M S Meltzer, C A Nacy.   

Abstract

Macrophages cultured with IL-2 and IFN-gamma before exposure to microorganisms developed the ability to resist infection with the obligate intracellular parasite, Leishmania major. The induction of this macrophage effector response was maximal by 6 to 8 h after lymphokine addition, and was independent of lymphokine treatment sequence. Activation of macrophages for resistance to infection was the result of the direct action of IL-2 and IFN-gamma on macrophages: the effector reaction was demonstrated in both resident peritoneal macrophages depleted of T cells and bone marrow-derived cells, a homogeneous macrophage population. Radiolabeled murine rIFN-gamma, human rIL-2, and mAb to the IL-2R (7D4), each bound to murine bone marrow-derived macrophages in a specific and saturable manner, which suggested that unstimulated macrophages have receptors for both lymphokines. Treatment of macrophages with IFN-gamma increased the specific binding of IL-2; treatment of cells with IL-2, however, did not up-regulate the IFN-gamma-R. Addition of protein or RNA synthesis inhibitors (cycloheximide, emetine, actinomycin D) during exposure to rIL-2 and rIFN-gamma totally abrogated the ability of macrophages to express this effector reaction; inhibitors of protein kinase C, PG, or calcium redistribution had no effect. Soluble polyclonal anti-TNF-alpha antibodies in culture fluids after activation of macrophages with IL-2 and IFN-gamma totally abrogated the expression of resistance to infection. The T cell growth hormone IL-2 acts as cofactor with IFN-gamma for induction of a macrophage antimicrobial activity, and TNF-alpha may be the effector molecule for resistance to infection regulated by these two lymphokines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Use of recombinant interleukin-2 to enhance adoptive transfer of resistance to Listeria monocytogenes infection.

Authors:  M Haak-Frendscho; C J Czuprynski
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

2.  Early activation of splenic macrophages by tumor necrosis factor alpha is important in determining the outcome of experimental histoplasmosis in mice.

Authors:  B A Wu-Hsieh; G S Lee; M Franco; F M Hofman
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

Review 3.  Immunobiology of experimental leishmaniasis.

Authors:  I Müller; U Fruth; J A Louis
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

4.  Phagocytosis of Giardia lamblia trophozoites by cytokine-activated macrophages.

Authors:  M Belosevic; C W Daniels
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

5.  Effects of cytokines on intracellular growth of Brucella abortus.

Authors:  X Jiang; C L Baldwin
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

6.  Cutting edge: the Idd3 genetic interval determines regulatory T cell function through CD11b+CD11c- APC.

Authors:  Ana C Anderson; Rucha Chandwaskar; David H Lee; Vijay K Kuchroo
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

7.  Cell-mediated responses of immunized vervet monkeys to defined Leishmania T-cell epitopes.

Authors:  A J Curry; A Jardim; J O Olobo; R W Olafson
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation.

Authors:  I Funke; O Prümmer; H Schrezenmeier; D Hardt; M Weiss; F Porzsolt; R Arnold; H Heimpel
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

9.  Response of scid mice to establishment of Leishmania major infection.

Authors:  R A Guy; M Belosevic
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

10.  Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.

Authors:  G Maass; W Schmidt; M Berger; F Schilcher; F Koszik; A Schneeberger; G Stingl; M L Birnstiel; T Schweighoffer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.